Neurovascular disease is a condition caused to nervous tissues vascular structure, neurons and blood vessels that leads to serious brain damages such as stroke, and cerebral hemorrhage. The global market for central nervous system disease was accounted to approximately $78 billion in 2010. Neurovascular disease market is mainly driven by the increase in number of patients suffering from neurological diseases. According to University of California, San Francisco (USCF), there are approximately 600,000 people suffering from stroke, out of which 10% are recovered. Almost 30% patients die due to stroke, and 60% of the patients remain disabled. The cost of care for these 60% patients accounted to approximately $8 billion. Cost of neurological disease treatment is lowering the growth for neurological disease. Companies are conducting clinical trials to commercialized cost effective therapies through mergers and acquisitions.

Medical device manufacturing companies are facing challenges in the form of commercialization in developing countries such as India, China, and Malaysia. However, increase in research on neurovascular therapies, and favorable government policies, would give the necessary push to the neurovascular market. This report gives intelligence about current market trends available and transition of these trends in future. Market intelligence of key patents granted by respective authorities is provided in this report.

The key companies included in this report are Medtronic, Stryker, Covidien (Ev3) , Johnson & Johnson (Micrus), Abbott Laboratories, Bayer AG, Boston Scientific Corporation, Cardiatis, S.A., Chestnut Medical Technologies, Inc., Johnson & Johnson, ITGI Medical Ltd.

KEY BENEFITS

• Key developmental strategies adopted by top market players engaged in this business, so that companies involved in development of neurovascular device can get competitive intelligence of their competitors
• Market estimation for therapeutic devices and geographic segment is derived from current market scenario and expected market trends
• Market attractiveness analysis has been included for various product segments, therapeutics, devices and geographic regions with detailed analysis of factors responsible for rapid growth of the market segments
• In depth analysis of key market drivers, restraints and opportunities of non-invasive diagnostic market with impact analysis
• Value chain analysis, Porter’s five force model, top investment pockets (GE9 Cell Matrix) are analyzed and presented in detail in the report so that the decision makers receive clear picture of neurovascular disease treatment market

 Key Market Segments

• By THERAPEUTICS
  • Endovascular cerebral aneurysm
  • Intracranial atherosclerotic disease
  • Chronic ischemic stroke
  • Acute ischemic stroke
• By DEVICES
  • Neurovascular liquid embolism
  • Intracranial stents & flow diverting devices
  • Neurovascular embolic coils
  • Carotid stents & embolic protection devices
  • Neurovascular thrombectomy devices
• By GEOGRAPHY
  • North America
  • Europe
  • Asia-Pacific
  • ROW

 
Key Market Players

• Academic Institutes
• Government and Private research laboratories
• Research based pharmaceutical companies
• Medical device manufacturing companies

• CHAPTER 1: INTRODUCTION

  • 1.1. Report Description

  • 1.2. Key Market Segments

  • 1.3. Key Benefits

  • 1.4. Research Methodology

    • 1.4.1. Primary Research

    • 1.4.2. Secondary Research

    • 1.4.3. Analyst Tools and Models

• CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

• CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope

  • 3.2. Key Findings

    • 3.2.1. Top Investment Pockets

    • 3.2.2. Top Winning Strategies

  • 3.3. Porter's Five Forces Analysis

    • 3.3.1. Bargaining Power of Suppliers

    • 3.3.2. Threat of New Entrants

    • 3.3.3. Threat of Substitutes

    • 3.3.4. Competitive Rivalry

    • 3.3.5. Bargaining Power among Buyers

  • 3.5. Market Dynamics

    • 3.5.1. Drivers

    • 3.5.2. Restraints

    • 3.5.3. Opportunities

• CHAPTER 4: NEUROVASCULAR MARKET, BY THERAPEUTICS

  • 4.1. Market Overview

    • 4.1.1 Market Size and Forecast, By Therapeutics

  • 4.2. Endovascular Cerebral Aneurysm

    • 4.2.1. Key Market Trends, Growth Factors and Opportunities

    • 4.2.2. Market Size and Forecast, By Region

    • 4.2.3. Market Share Analysis, By Country

  • 4.3. Intracranial Atherosclerotic Disease

    • 4.3.1. Key Market Trends, Growth Factors and Opportunities

    • 4.3.2. Market Size and Forecast, By Region

    • 4.3.3. Market Share Analysis, By Country

  • 4.4. Chronic Ischemic Stroke

    • 4.4.1. Key Market Trends, Growth Factors and Opportunities

    • 4.4.2. Market Size and Forecast, By Region

    • 4.4.3. Market Share Analysis, By Country

  • 4.5. Acute Ischemic Stroke

    • 4.5.1. Key Market Trends, Growth Factors and Opportunities

    • 4.5.2. Market Size and Forecast, By Region

    • 4.5.3. Market Share Analysis, By Country

• CHAPTER 5: NEUROVASCULAR MARKET, BY DEVICES

  • 5.1. Market Overview

    • 5.1.1 Market Size and Forecast, By Devices

  • 5.2. Neurovascular Liquid Embolism

    • 5.2.1. Key Market Trends, Growth Factors and Opportunities

    • 5.2.2. Market Size and Forecast, By Region

    • 5.2.3. Market Share Analysis, By Country

  • 5.3. Intracranial Stents And Flow Diverting Devices

    • 5.3.1. Key Market Trends, Growth Factors and Opportunities

    • 5.3.2. Market Size and Forecast, By Region

    • 5.3.3. Market Share Analysis, By Country

  • 5.4. Neurovascular Embolic Coils

    • 5.4.1. Key Market Trends, Growth Factors and Opportunities

    • 5.4.2. Market Size and Forecast, By Region

    • 5.4.3. Market Share Analysis, By Country

  • 5.5. Carotid Stents And Embolic Protection Devices

    • 5.5.1. Key Market Trends, Growth Factors and Opportunities

    • 5.5.2. Market Size and Forecast, By Region

    • 5.5.3. Market Share Analysis, By Country

  • 5.6. Neurovascular Thrombectomy Devices

    • 5.6.1. Key Market Trends, Growth Factors and Opportunities

    • 5.6.2. Market Size and Forecast, By Region

    • 5.6.3. Market Share Analysis, By Country

• CHAPTER 6: NEUROVASCULAR MARKET, BY REGION

  • 6.1. Market Overview

    • 6.1.1 Market Size and Forecast, By Region

  • 6.2. North America

    • 6.2.1. Key Market Trends and Opportunities

    • 6.2.2. Market Size and Forecast, By Therapeutics

    • 6.2.3. Market Size and Forecast, By Devices

    • 6.2.4. Market Size and Forecast, By Country

    • 6.2.5. U.S. Neurovascular Market

      • 6.2.5.1. Market Size and Forecast, By Therapeutics

      • 6.2.5.2. Market Size and Forecast, By Devices

    • 6.2.6. Canada Neurovascular Market

      • 6.2.6.1. Market Size and Forecast, By Therapeutics

      • 6.2.6.2. Market Size and Forecast, By Devices

    • 6.2.7. Mexico Neurovascular Market

      • 6.2.7.1. Market Size and Forecast, By Therapeutics

      • 6.2.7.2. Market Size and Forecast, By Devices

  • 6.3. Europe

    • 6.3.1. Key Market Trends and Opportunities

    • 6.3.2. Market Size and Forecast, By Therapeutics

    • 6.3.3. Market Size and Forecast, By Devices

    • 6.3.4. Market Size and Forecast, By Country

    • 6.3.5. France Neurovascular Market

      • 6.3.5.1. Market Size and Forecast, By Therapeutics

      • 6.3.5.2. Market Size and Forecast, By Devices

    • 6.3.6. Germany Neurovascular Market

      • 6.3.6.1. Market Size and Forecast, By Therapeutics

      • 6.3.6.2. Market Size and Forecast, By Devices

    • 6.3.7. Italy Neurovascular Market

      • 6.3.7.1. Market Size and Forecast, By Therapeutics

      • 6.3.7.2. Market Size and Forecast, By Devices

    • 6.3.8. Spain Neurovascular Market

      • 6.3.8.1. Market Size and Forecast, By Therapeutics

      • 6.3.8.2. Market Size and Forecast, By Devices

    • 6.3.9. UK Neurovascular Market

      • 6.3.9.1. Market Size and Forecast, By Therapeutics

      • 6.3.9.2. Market Size and Forecast, By Devices

    • 6.3.10. Russia Neurovascular Market

      • 6.3.10.1. Market Size and Forecast, By Therapeutics

      • 6.3.10.2. Market Size and Forecast, By Devices

    • 6.3.11. Rest Of Europe Neurovascular Market

      • 6.3.11.1. Market Size and Forecast, By Therapeutics

      • 6.3.11.2. Market Size and Forecast, By Devices

  • 6.4. Asia-Pacific

    • 6.4.1. Key Market Trends and Opportunities

    • 6.4.2. Market Size and Forecast, By Therapeutics

    • 6.4.3. Market Size and Forecast, By Devices

    • 6.4.4. Market Size and Forecast, By Country

    • 6.4.5. China Neurovascular Market

      • 6.4.5.1. Market Size and Forecast, By Therapeutics

      • 6.4.5.2. Market Size and Forecast, By Devices

    • 6.4.6. Japan Neurovascular Market

      • 6.4.6.1. Market Size and Forecast, By Therapeutics

      • 6.4.6.2. Market Size and Forecast, By Devices

    • 6.4.7. India Neurovascular Market

      • 6.4.7.1. Market Size and Forecast, By Therapeutics

      • 6.4.7.2. Market Size and Forecast, By Devices

    • 6.4.8. South Korea Neurovascular Market

      • 6.4.8.1. Market Size and Forecast, By Therapeutics

      • 6.4.8.2. Market Size and Forecast, By Devices

    • 6.4.9. Australia Neurovascular Market

      • 6.4.9.1. Market Size and Forecast, By Therapeutics

      • 6.4.9.2. Market Size and Forecast, By Devices

    • 6.4.10. Thailand Neurovascular Market

      • 6.4.10.1. Market Size and Forecast, By Therapeutics

      • 6.4.10.2. Market Size and Forecast, By Devices

    • 6.4.11. Malaysia Neurovascular Market

      • 6.4.11.1. Market Size and Forecast, By Therapeutics

      • 6.4.11.2. Market Size and Forecast, By Devices

    • 6.4.12. Indonesia Neurovascular Market

      • 6.4.12.1. Market Size and Forecast, By Therapeutics

      • 6.4.12.2. Market Size and Forecast, By Devices

    • 6.4.13. Rest of Asia Pacific Neurovascular Market

      • 6.4.13.1. Market Size and Forecast, By Therapeutics

      • 6.4.13.2. Market Size and Forecast, By Devices

  • 6.5. LAMEA

    • 6.5.1. Key Market Trends and Opportunities

    • 6.5.2. Market Size and Forecast, By Therapeutics

    • 6.5.3. Market Size and Forecast, By Devices

    • 6.5.4. Market Size and Forecast, By Country

    • 6.5.5. Brazil Neurovascular Market

      • 6.5.5.1. Market Size and Forecast, By Therapeutics

      • 6.5.5.2. Market Size and Forecast, By Devices

    • 6.5.6. South Africa Neurovascular Market

      • 6.5.6.1. Market Size and Forecast, By Therapeutics

      • 6.5.6.2. Market Size and Forecast, By Devices

    • 6.5.7. Saudi Arabia Neurovascular Market

      • 6.5.7.1. Market Size and Forecast, By Therapeutics

      • 6.5.7.2. Market Size and Forecast, By Devices

    • 6.5.8. UAE Neurovascular Market

      • 6.5.8.1. Market Size and Forecast, By Therapeutics

      • 6.5.8.2. Market Size and Forecast, By Devices

    • 6.5.9. Argentina Neurovascular Market

      • 6.5.9.1. Market Size and Forecast, By Therapeutics

      • 6.5.9.2. Market Size and Forecast, By Devices

    • 6.5.10. Rest of LAMEA Neurovascular Market

      • 6.5.10.1. Market Size and Forecast, By Therapeutics

      • 6.5.10.2. Market Size and Forecast, By Devices

• CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction

  • 7.2. Top Winning Strategies

  • 7.3. Product Mapping Of Top 10 Player

  • 7.4. Competitive Dashboard

  • 7.5. Competitive Heatmap

  • 7.6. Top Player Positioning, 2024

• CHAPTER 8: COMPANY PROFILES

  • 8.1. Medical Device Manufacturing Companies

    • 8.1.1. Company Overview

    • 8.1.2. Key Executives

    • 8.1.3. Company Snapshot

    • 8.1.4. Operating Business Segments

    • 8.1.5. Product Portfolio

    • 8.1.6. Business Performance

    • 8.1.7. Key Strategic Moves and Developments

  • 8.2. Research Based Pharmaceutical Companies

    • 8.2.1. Company Overview

    • 8.2.2. Key Executives

    • 8.2.3. Company Snapshot

    • 8.2.4. Operating Business Segments

    • 8.2.5. Product Portfolio

    • 8.2.6. Business Performance

    • 8.2.7. Key Strategic Moves and Developments

  • 8.3. Academic Institutes

    • 8.3.1. Company Overview

    • 8.3.2. Key Executives

    • 8.3.3. Company Snapshot

    • 8.3.4. Operating Business Segments

    • 8.3.5. Product Portfolio

    • 8.3.6. Business Performance

    • 8.3.7. Key Strategic Moves and Developments

  • 8.4. Government And Private Research Laboratories

    • 8.4.1. Company Overview

    • 8.4.2. Key Executives

    • 8.4.3. Company Snapshot

    • 8.4.4. Operating Business Segments

    • 8.4.5. Product Portfolio

    • 8.4.6. Business Performance

    • 8.4.7. Key Strategic Moves and Developments

• LIST OF TABLES

• TABLE 1. GLOBAL NEUROVASCULAR MARKET, BY THERAPEUTICS, 2025-2033 ($MILLION)
• TABLE 2. GLOBAL NEUROVASCULAR MARKET FOR ENDOVASCULAR CEREBRAL ANEURYSM, BY REGION, 2025-2033 ($MILLION)
• TABLE 3. GLOBAL NEUROVASCULAR MARKET FOR INTRACRANIAL ATHEROSCLEROTIC DISEASE, BY REGION, 2025-2033 ($MILLION)
• TABLE 4. GLOBAL NEUROVASCULAR MARKET FOR CHRONIC ISCHEMIC STROKE, BY REGION, 2025-2033 ($MILLION)
• TABLE 5. GLOBAL NEUROVASCULAR MARKET FOR ACUTE ISCHEMIC STROKE, BY REGION, 2025-2033 ($MILLION)
• TABLE 6. GLOBAL NEUROVASCULAR MARKET, BY DEVICES, 2025-2033 ($MILLION)
• TABLE 7. GLOBAL NEUROVASCULAR MARKET FOR NEUROVASCULAR LIQUID EMBOLISM, BY REGION, 2025-2033 ($MILLION)
• TABLE 8. GLOBAL NEUROVASCULAR MARKET FOR INTRACRANIAL STENTS AND FLOW DIVERTING DEVICES, BY REGION, 2025-2033 ($MILLION)
• TABLE 9. GLOBAL NEUROVASCULAR MARKET FOR NEUROVASCULAR EMBOLIC COILS, BY REGION, 2025-2033 ($MILLION)
• TABLE 10. GLOBAL NEUROVASCULAR MARKET FOR CAROTID STENTS AND EMBOLIC PROTECTION DEVICES, BY REGION, 2025-2033 ($MILLION)
• TABLE 11. GLOBAL NEUROVASCULAR MARKET FOR NEUROVASCULAR THROMBECTOMY DEVICES, BY REGION, 2025-2033 ($MILLION)
• TABLE 12. GLOBAL NEUROVASCULAR MARKET, BY REGION, 2025-2033 ($MILLION)
• TABLE 13. NORTH AMERICA NEUROVASCULAR, BY REGION, 2025-2033 ($MILLION)
• TABLE 14. NORTH AMERICA NEUROVASCULAR, BY THERAPEUTICS, 2025-2033 ($MILLION)
• TABLE 15. NORTH AMERICA NEUROVASCULAR, BY DEVICES, 2025-2033 ($MILLION)
• TABLE 16. U.S. NEUROVASCULAR, BY THERAPEUTICS, 2025-2033 ($MILLION)
• TABLE 17. U.S. NEUROVASCULAR, BY DEVICES, 2025-2033 ($MILLION)
• TABLE 18. CANADA NEUROVASCULAR, BY THERAPEUTICS, 2025-2033 ($MILLION)
• TABLE 19. CANADA NEUROVASCULAR, BY DEVICES, 2025-2033 ($MILLION)
• TABLE 20. MEXICO NEUROVASCULAR, BY THERAPEUTICS, 2025-2033 ($MILLION)
• TABLE 21. MEXICO NEUROVASCULAR, BY DEVICES, 2025-2033 ($MILLION)
• TABLE 22. EUROPE NEUROVASCULAR, BY REGION, 2025-2033 ($MILLION)
• TABLE 23. EUROPE NEUROVASCULAR, BY THERAPEUTICS, 2025-2033 ($MILLION)
• TABLE 24. EUROPE NEUROVASCULAR, BY DEVICES, 2025-2033 ($MILLION)
• TABLE 25. FRANCE NEUROVASCULAR, BY THERAPEUTICS, 2025-2033 ($MILLION)
• TABLE 26. FRANCE NEUROVASCULAR, BY DEVICES, 2025-2033 ($MILLION)
• TABLE 27. GERMANY NEUROVASCULAR, BY THERAPEUTICS, 2025-2033 ($MILLION)
• TABLE 28. GERMANY NEUROVASCULAR, BY DEVICES, 2025-2033 ($MILLION)
• TABLE 29. ITALY NEUROVASCULAR, BY THERAPEUTICS, 2025-2033 ($MILLION)
• TABLE 30. ITALY NEUROVASCULAR, BY DEVICES, 2025-2033 ($MILLION)
• TABLE 31. SPAIN NEUROVASCULAR, BY THERAPEUTICS, 2025-2033 ($MILLION)
• TABLE 32. SPAIN NEUROVASCULAR, BY DEVICES, 2025-2033 ($MILLION)
• TABLE 33. UK NEUROVASCULAR, BY THERAPEUTICS, 2025-2033 ($MILLION)
• TABLE 34. UK NEUROVASCULAR, BY DEVICES, 2025-2033 ($MILLION)
• TABLE 35. RUSSIA NEUROVASCULAR, BY THERAPEUTICS, 2025-2033 ($MILLION)
• TABLE 36. RUSSIA NEUROVASCULAR, BY DEVICES, 2025-2033 ($MILLION)
• TABLE 37. REST OF EUROPE NEUROVASCULAR, BY THERAPEUTICS, 2025-2033 ($MILLION)
• TABLE 38. REST OF EUROPE NEUROVASCULAR, BY DEVICES, 2025-2033 ($MILLION)
• TABLE 39. ASIA-PACIFIC NEUROVASCULAR, BY REGION, 2025-2033 ($MILLION)
• TABLE 40. ASIA-PACIFIC NEUROVASCULAR, BY THERAPEUTICS, 2025-2033 ($MILLION)
• TABLE 41. ASIA-PACIFIC NEUROVASCULAR, BY DEVICES, 2025-2033 ($MILLION)
• TABLE 42. CHINA NEUROVASCULAR, BY THERAPEUTICS, 2025-2033 ($MILLION)
• TABLE 43. CHINA NEUROVASCULAR, BY DEVICES, 2025-2033 ($MILLION)
• TABLE 44. JAPAN NEUROVASCULAR, BY THERAPEUTICS, 2025-2033 ($MILLION)
• TABLE 45. JAPAN NEUROVASCULAR, BY DEVICES, 2025-2033 ($MILLION)
• TABLE 46. INDIA NEUROVASCULAR, BY THERAPEUTICS, 2025-2033 ($MILLION)
• TABLE 47. INDIA NEUROVASCULAR, BY DEVICES, 2025-2033 ($MILLION)
• TABLE 48. SOUTH KOREA NEUROVASCULAR, BY THERAPEUTICS, 2025-2033 ($MILLION)
• TABLE 49. SOUTH KOREA NEUROVASCULAR, BY DEVICES, 2025-2033 ($MILLION)
• TABLE 50. AUSTRALIA NEUROVASCULAR, BY THERAPEUTICS, 2025-2033 ($MILLION)
• TABLE 51. AUSTRALIA NEUROVASCULAR, BY DEVICES, 2025-2033 ($MILLION)
• TABLE 52. THAILAND NEUROVASCULAR, BY THERAPEUTICS, 2025-2033 ($MILLION)
• TABLE 53. THAILAND NEUROVASCULAR, BY DEVICES, 2025-2033 ($MILLION)
• TABLE 54. MALAYSIA NEUROVASCULAR, BY THERAPEUTICS, 2025-2033 ($MILLION)
• TABLE 55. MALAYSIA NEUROVASCULAR, BY DEVICES, 2025-2033 ($MILLION)
• TABLE 56. INDONESIA NEUROVASCULAR, BY THERAPEUTICS, 2025-2033 ($MILLION)
• TABLE 57. INDONESIA NEUROVASCULAR, BY DEVICES, 2025-2033 ($MILLION)
• TABLE 58. REST OF ASIA PACIFIC NEUROVASCULAR, BY THERAPEUTICS, 2025-2033 ($MILLION)
• TABLE 59. REST OF ASIA PACIFIC NEUROVASCULAR, BY DEVICES, 2025-2033 ($MILLION)
• TABLE 60. LAMEA NEUROVASCULAR, BY REGION, 2025-2033 ($MILLION)
• TABLE 61. LAMEA NEUROVASCULAR, BY THERAPEUTICS, 2025-2033 ($MILLION)
• TABLE 62. LAMEA NEUROVASCULAR, BY DEVICES, 2025-2033 ($MILLION)
• TABLE 63. BRAZIL NEUROVASCULAR, BY THERAPEUTICS, 2025-2033 ($MILLION)
• TABLE 64. BRAZIL NEUROVASCULAR, BY DEVICES, 2025-2033 ($MILLION)
• TABLE 65. SOUTH AFRICA NEUROVASCULAR, BY THERAPEUTICS, 2025-2033 ($MILLION)
• TABLE 66. SOUTH AFRICA NEUROVASCULAR, BY DEVICES, 2025-2033 ($MILLION)
• TABLE 67. SAUDI ARABIA NEUROVASCULAR, BY THERAPEUTICS, 2025-2033 ($MILLION)
• TABLE 68. SAUDI ARABIA NEUROVASCULAR, BY DEVICES, 2025-2033 ($MILLION)
• TABLE 69. UAE NEUROVASCULAR, BY THERAPEUTICS, 2025-2033 ($MILLION)
• TABLE 70. UAE NEUROVASCULAR, BY DEVICES, 2025-2033 ($MILLION)
• TABLE 71. ARGENTINA NEUROVASCULAR, BY THERAPEUTICS, 2025-2033 ($MILLION)
• TABLE 72. ARGENTINA NEUROVASCULAR, BY DEVICES, 2025-2033 ($MILLION)
• TABLE 73. REST OF LAMEA NEUROVASCULAR, BY THERAPEUTICS, 2025-2033 ($MILLION)
• TABLE 74. REST OF LAMEA NEUROVASCULAR, BY DEVICES, 2025-2033 ($MILLION)
• TABLE 75. MEDICAL DEVICE MANUFACTURING COMPANIES: KEY EXECUTIVES
• TABLE 76. MEDICAL DEVICE MANUFACTURING COMPANIES: COMPANY SNAPSHOT
• TABLE 77. MEDICAL DEVICE MANUFACTURING COMPANIES: OPERATING SEGMENTS
• TABLE 78. MEDICAL DEVICE MANUFACTURING COMPANIES: PRODUCT PORTFOLIO
• TABLE 79. MEDICAL DEVICE MANUFACTURING COMPANIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 80. RESEARCH BASED PHARMACEUTICAL COMPANIES: KEY EXECUTIVES
• TABLE 81. RESEARCH BASED PHARMACEUTICAL COMPANIES: COMPANY SNAPSHOT
• TABLE 82. RESEARCH BASED PHARMACEUTICAL COMPANIES: OPERATING SEGMENTS
• TABLE 83. RESEARCH BASED PHARMACEUTICAL COMPANIES: PRODUCT PORTFOLIO
• TABLE 84. RESEARCH BASED PHARMACEUTICAL COMPANIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 85. ACADEMIC INSTITUTES: KEY EXECUTIVES
• TABLE 86. ACADEMIC INSTITUTES: COMPANY SNAPSHOT
• TABLE 87. ACADEMIC INSTITUTES: OPERATING SEGMENTS
• TABLE 88. ACADEMIC INSTITUTES: PRODUCT PORTFOLIO
• TABLE 89. ACADEMIC INSTITUTES: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 90. GOVERNMENT AND PRIVATE RESEARCH LABORATORIES: KEY EXECUTIVES
• TABLE 91. GOVERNMENT AND PRIVATE RESEARCH LABORATORIES: COMPANY SNAPSHOT
• TABLE 92. GOVERNMENT AND PRIVATE RESEARCH LABORATORIES: OPERATING SEGMENTS
• TABLE 93. GOVERNMENT AND PRIVATE RESEARCH LABORATORIES: PRODUCT PORTFOLIO
• TABLE 94. GOVERNMENT AND PRIVATE RESEARCH LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS

• LIST OF FIGURES

• FIGURE 1. GLOBAL NEUROVASCULAR MARKET SEGMENTATION
• FIGURE 2. GLOBAL NEUROVASCULAR MARKET
• FIGURE 3. SEGMENTATION NEUROVASCULAR MARKET
• FIGURE 4. TOP INVESTMENT POCKET IN NEUROVASCULAR MARKET
• FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
• FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
• FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
• FIGURE 8. LOW THREAT OF SUBSTITUTION
• FIGURE 9. HIGH COMPETITIVE RIVALRY
• FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALNEUROVASCULAR MARKET
• FIGURE 11. NEUROVASCULAR MARKET SEGMENTATION, BY BY THERAPEUTICS
• FIGURE 12. NEUROVASCULAR MARKET FOR ENDOVASCULAR CEREBRAL ANEURYSM, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 13. NEUROVASCULAR MARKET FOR INTRACRANIAL ATHEROSCLEROTIC DISEASE, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 14. NEUROVASCULAR MARKET FOR CHRONIC ISCHEMIC STROKE, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 15. NEUROVASCULAR MARKET FOR ACUTE ISCHEMIC STROKE, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 16. NEUROVASCULAR MARKET SEGMENTATION, BY BY DEVICES
• FIGURE 17. NEUROVASCULAR MARKET FOR NEUROVASCULAR LIQUID EMBOLISM, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 18. NEUROVASCULAR MARKET FOR INTRACRANIAL STENTS AND FLOW DIVERTING DEVICES, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 19. NEUROVASCULAR MARKET FOR NEUROVASCULAR EMBOLIC COILS, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 20. NEUROVASCULAR MARKET FOR CAROTID STENTS AND EMBOLIC PROTECTION DEVICES, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 21. NEUROVASCULAR MARKET FOR NEUROVASCULAR THROMBECTOMY DEVICES, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 22. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
• FIGURE 23. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
• FIGURE 24. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
• FIGURE 25. PRODUCT MAPPING OF TOP 10 PLAYERS
• FIGURE 26. COMPETITIVE DASHBOARD
• FIGURE 27. COMPETITIVE HEATMAP: NEUROVASCULAR MARKET
• FIGURE 28. TOP PLAYER POSITIONING, 2024
• FIGURE 29. MEDICAL DEVICE MANUFACTURING COMPANIES: NET SALES, 2022-2024 ($MILLION)
• FIGURE 30. MEDICAL DEVICE MANUFACTURING COMPANIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 31. MEDICAL DEVICE MANUFACTURING COMPANIES: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 32. RESEARCH BASED PHARMACEUTICAL COMPANIES: NET SALES, 2022-2024 ($MILLION)
• FIGURE 33. RESEARCH BASED PHARMACEUTICAL COMPANIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 34. RESEARCH BASED PHARMACEUTICAL COMPANIES: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 35. ACADEMIC INSTITUTES: NET SALES, 2022-2024 ($MILLION)
• FIGURE 36. ACADEMIC INSTITUTES: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 37. ACADEMIC INSTITUTES: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 38. GOVERNMENT AND PRIVATE RESEARCH LABORATORIES: NET SALES, 2022-2024 ($MILLION)
• FIGURE 39. GOVERNMENT AND PRIVATE RESEARCH LABORATORIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 40. GOVERNMENT AND PRIVATE RESEARCH LABORATORIES: REVENUE SHARE, BY REGION, 2024 (%)